We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00456924
Recruitment Status : Completed
First Posted : April 5, 2007
Last Update Posted : June 17, 2010
Information provided by:
HRA Pharma

Brief Summary:
The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.

Condition or disease Intervention/treatment Phase
Contraception Gynecologic Diseases Drug: VA2914 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium
Study Start Date : January 2004
Study Completion Date : December 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. ovarian hormones
  2. follicular development
  3. endometrial histology

Secondary Outcome Measures :
  1. menstural bleeding patterns
  2. cervical mucus
  3. VA2914 concentration
  4. adverse events
  5. laboratory parameters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women in good general health with regular, ovulatory menstrual cycles
  • age 18-35
  • not pregnant
  • not sexually active or reliably use barrier methods of contraception
  • normal liver and renal functions and normal laboratory exams

Exclusion Criteria:

  • pregnant or breastfeeding
  • oral contraception, IUD or other hormonal treatment
  • use of agents known to induce hepatic P450
  • cardiovascular disorder
  • hepatic, renal, or gastrointestinal disorder
  • metrorrhagia
  • abnormal transvaginal ultrasound (at baseline)
  • history of abnormal endometrial biopsy,
  • cancer
  • depression
  • mental illness
  • epilepsy
  • migraines
  • abnormal Pap Smear requiring further exploratory examination
  • anovulatory cycle before treatment
  • extreme overweight or underweight (body mass index < 16 ou >28)
  • subjects unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
  • use of narcotics
  • more than 10 cigarettes per day, more than 2 glasses of wine/beer per day
  • surgical procedures planned in the 6 months following screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00456924

Liege University Hospital
Liege, Belgium
Sainte Rosalie Clinique
Liege, Belgium
Antoine Beclere Hospital
Clamart, France
Saint Antoine Hospital
Paris, France
Sponsors and Collaborators
HRA Pharma
Principal Investigator: Philippe Bouchard, MD Saint Antoine Hospital, Paris, France

ClinicalTrials.gov Identifier: NCT00456924     History of Changes
Other Study ID Numbers: 2914-002
First Posted: April 5, 2007    Key Record Dates
Last Update Posted: June 17, 2010
Last Verified: June 2010

Keywords provided by HRA Pharma:
progesterone receptor modulator

Additional relevant MeSH terms:
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs